EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review

Sergio De Santos Belinchón iD, Cristina Ausín García, Pablo Daniel Lorenzo Barcia iD, Tatiana Pire García, Héctor Balastegui Martín, Cecilia Muñoz Delgado, Maria Victoria Villalba García, Cristina Lavilla Olleros iD

Internal Medicine Journal · 2026

DOI: 10.1111/imj.70233 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Sergio De Santos Belinchón und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Schnitzler Syndrome, Interleukin 1 Receptor Antagonist Protein, Antibodies, Monoclonal. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schnitzler syndrome is a rare autoinflammatory syndrome caused by a dysregulation of the interleukin‐1β signalling pathway. Symptoms tend to appear in middle age and include urticariform skin lesions, fever, bone pain, lymphadenopathy and IgM monoclonal gammopathy. Interleukin‐1 (IL‐1) targeted therapy constitutes the basis for treatment and can lead to complete resolution of symptoms. We report a case of Schnitzler syndrome in a 49‐year‐old man refractory to anakinra and subsequently treated successfully with canakinumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Schnitzler SyndromeInterleukin 1 Receptor Antagonist ProteinAntibodies, MonoclonalHumansAntibodies, Monoclonal, HumanizedMaleMiddle AgedTreatment OutcomeAntirheumatic AgentsDrug Resistance

Stichwörter der Autor:innen

Schnitzler syndromeanakinracanakinumabmonoclonal gammopathyurticarial rash

Substanzen

Antibodies, Monoclonal, HumanizedcanakinumabInterleukin 1 Receptor Antagonist ProteinAntibodies, MonoclonalAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Gregorio Marañón Institute of Health Research, Madrid, Spain.
  • Department of Emergency, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Department of Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

ORCID-Profile: Sergio De Santos Belinchón, Pablo Daniel Lorenzo Barcia, Cristina Lavilla Olleros

Zitieren

APA

De Santos Belinchón, S., Ausín García, C., Lorenzo Barcia, P. D., Pire García, T., Balastegui Martín, H., Muñoz Delgado, C., Villalba García, M. V., & Lavilla Olleros, C. (2026). Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review. Internal Medicine Journal. https://doi.org/10.1111/imj.70233

Vancouver

De Santos Belinchón S, Ausín García C, Lorenzo Barcia PD, Pire García T, Balastegui Martín H, Muñoz Delgado C, et al. Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review. Internal Medicine Journal. 2026. doi:10.1111/imj.70233

BibTeX
@article{DeSantosBelinchn2026,
  author = {De Santos Belinchón, Sergio and Ausín García, Cristina and Lorenzo Barcia, Pablo Daniel and Pire García, Tatiana and Balastegui Martín, Héctor and Muñoz Delgado, Cecilia and Villalba García, Maria Victoria and Lavilla Olleros, Cristina},
  title = {Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70233}
}
Kostenlos starten →